Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Panizo

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
Annals of Hematology|May 6, 2020
Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patientsEva González-Barca, Francisco Javier Capote, Jose Gómez-Codina, et al.
British Journal of Haematology|October 2, 2019
Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella studyRicardo García-Muñoz, Cristina Quero, Ernesto Pérez-Persona, et al.
Journal for Immunotherapy of Cancer|February 28, 2023
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphomaJavier Melchor, Marcos Garcia-Lacarte, Sara C Grijalba, et al.
Leukemia & Lymphoma|May 31, 2018
A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignanciesJan de Jong, Peter Hellemans, Severijn De Wilde, et al.
Blood|June 24, 2010
Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphomaJose A Richter-Larrea, Eloy F Robles, Vicente Fresquet, et al.
British Journal of Haematology|July 29, 2014
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trialEmilia Pardal, Mónica Coronado, Alejandro Martín, et al.
Haematologica|October 29, 2013
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trialJavier Briones, Silvana Novelli, José A García-Marco, et al.
The Lancet. Haematology|January 8, 2024
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 studyPau Abrisqueta, Eva González-Barca, Carlos Panizo, et al.
Journal of the National Cancer Institute|September 21, 2006
Clinical benefit associated with idiotypic vaccination in patients with follicular lymphomaSusana Inogès, Mercedes Rodrìguez-Calvillo, Natalia Zabalegui, et al.
Haematologica|December 2, 2017
Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasmsJon Celay, Teresa Lozano, Axel R Concepcion, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Annals of Hematology|May 6, 2020
Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patientsEva González-Barca, Francisco Javier Capote, Jose Gómez-Codina, et al.
British Journal of Haematology|October 2, 2019
Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella studyRicardo García-Muñoz, Cristina Quero, Ernesto Pérez-Persona, et al.
Journal for Immunotherapy of Cancer|February 28, 2023
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphomaJavier Melchor, Marcos Garcia-Lacarte, Sara C Grijalba, et al.
Leukemia & Lymphoma|May 31, 2018
A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignanciesJan de Jong, Peter Hellemans, Severijn De Wilde, et al.
Blood|June 24, 2010
Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphomaJose A Richter-Larrea, Eloy F Robles, Vicente Fresquet, et al.
British Journal of Haematology|July 29, 2014
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trialEmilia Pardal, Mónica Coronado, Alejandro Martín, et al.
Haematologica|October 29, 2013
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trialJavier Briones, Silvana Novelli, José A García-Marco, et al.
The Lancet. Haematology|January 8, 2024
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 studyPau Abrisqueta, Eva González-Barca, Carlos Panizo, et al.
Journal of the National Cancer Institute|September 21, 2006
Clinical benefit associated with idiotypic vaccination in patients with follicular lymphomaSusana Inogès, Mercedes Rodrìguez-Calvillo, Natalia Zabalegui, et al.
Haematologica|December 2, 2017
Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasmsJon Celay, Teresa Lozano, Axel R Concepcion, et al.
Pageof 6